TABLE 4.

Cox regression analysis of the IRG signature with survival.

Variables		Univariable analysis				Multivariable analysis
		HR	95% CI of HR		P	HR	95% CI of HR		P
			lower	upper			lower	upper
The TCGA group
Age	>68 vs.≤68	1.59	1.08	2.34	0.02*	1.78	1.2	2.64	<0.001***
Gender	Male vs. Female	1.15	0.79	1.69	0.47	0.91	0.61	1.34	0.62
Tumor stage	III, IV Vs. I, II	1.04	1.01	1.06	<0.001***	1.03	1	1.05	0.02*
Signature	High risk vs. Low risk	4.49	2.79	7.23	<0.001***	4.56	2.81	7.4	<0.001***
The GSE39582 group
Age	>68 vs. ≤68	1.89	1.42	2.51	<0.001***	2.31	1.72	3.10	<0.001***
Gender	Male vs. Female	1.31	0.98	1.74	0.07	1.54	1.15	2.06	0.004**
Tumor stage	III, IV Vs. I, II	1.94	1.59	2.36	<0.001***	2.08	1.69	2.56	<0.001***
Signature	High risk vs. Low risk	1.7	1.27	2.26	<0.001***	1.55	1.16	2.07	0.003**
The GSE17538 group
Age	>68 vs. ≤68	1.22	0.80	1.84	0.36	1.89	1.22	2.93	<0.001***
Gender	Male vs. Female	1.03	0.68	1.56	0.88	1.11	0.71	1.73	0.65
Tumor stage	III, IV vs. I, II	2.90	2.20	3.83	<0.001***	2.99	2.25	3.99	<0.001***
Signature	High risk vs. Low risk	1.65	1.08	2.51	0.02*	1.72	1.10	2.69	0.02*

In both the training and validation groups, patients’ disease stage, age, sex, and IRG signature were tested in univariate and multivariate COX regression, in which age, tumor stage, and IRG signature were independent prognostic factors. The hazard ratios, 95% CIs, and corresponding p-values are given. IRG, Immune-related gene. * P < 0.05; ** P < 0.01; *** P < 0.001.